Skip to main content
LXRX
NASDAQ Life Sciences

Lexicon Pharmaceuticals 公布第四季度每股亏损 4 美分

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
7
Price
$1.63
Mkt Cap
$644.61M
52W Low
$0.298
52W High
$1.83
Market data snapshot near publication time

summarizeSummary

Lexicon Pharmaceuticals 宣布第四季度每股亏损 4 美分。虽然标题提供了一个关键的财务指标，但它缺乏关于分析师预测、收入数据或未来指导的背景信息。这些信息对于投资者全面评估公司的财务状况和经营业绩至关重要。交易者需要审阅完整的财务报告，以全面了解结果以及管理层对未来前景的任何评论。

在该公告发布时，LXRX的交易价格为$1.63，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6.4亿。 52周交易区间为$0.30至$1.83。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed LXRX - Latest Insights

LXRX
Mar 16, 2026, 4:04 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Shareholders to Vote on New Equity Plans and Charter Amendment at Annual Meeting
Sentiment: Neutral
View Wiseek Article
LXRX
Mar 16, 2026, 4:03 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Doubling Authorized Shares, Expanding Equity Plans
Sentiment: Negative
View Wiseek Article
LXRX
Mar 05, 2026, 4:50 PM EST
Filing Type: 10-K
Importance Score:
8
Lexicon Pharmaceuticals Reports Reduced Annual Loss, Increased Revenue, and Secures $96.7M in New Financing
Sentiment: Positive
View Wiseek Article
LXRX
Mar 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Lexicon Pharmaceuticals Reports Q4 2025 Results, Secures Over $100M in New Capital, Advances Key Pipeline Programs
Sentiment: Positive
View Wiseek Article
LXRX
Mar 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Lexicon Pharmaceuticals Reports Q4 Loss of 4 Cents Per Share
Sentiment: Neutral
View Wiseek Article
LXRX
Feb 17, 2026, 4:12 PM EST
Filing Type: PRE 14A
Importance Score:
8
Stockholders to Vote on Doubling Authorized Shares to 900M, Expanding Equity Plans
Sentiment: Negative
View Wiseek Article
LXRX
Feb 04, 2026, 4:25 PM EST
Filing Type: 4
Importance Score:
9
Director & 10% Owner Group Invests $55M in Lexicon Pharmaceuticals
Sentiment: Positive
View Wiseek Article
LXRX
Feb 02, 2026, 9:54 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Major Shareholders and Chairman Invest $70M in Offering, Boosting Stake to 48.2%
Sentiment: Positive
View Wiseek Article
LXRX
Feb 02, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
8
Lexicon Pharmaceuticals Finalizes $94.6M Offering and Private Placement, Invus to Hold 51% Stake
Sentiment: Neutral
View Wiseek Article
LXRX
Feb 02, 2026, 12:07 PM EST
Filing Type: 424B5
Importance Score:
8
Lexicon Pharmaceuticals Finalizes $94.6M Public Offering and Private Placement at Discounted Price
Sentiment: Negative
View Wiseek Article